Skip to main content
OABI
NASDAQ Industrial Applications And Services

OmniAb Q3 Revenue $4.0M, Raises 2026 Revenue Guidance to $35-39M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5
Mkt Cap
$760.392M
52W Low
$1.3
52W High
$5.43
52W Position info
285% above low
Off High info
7.9% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

OABI has more than doubled off its 52-week low of $1.3.

Summary

OmniAb reported Q3 2026 revenue of $4.0 million versus $2.2 million a year ago and raised full-year revenue guidance to $35-39 million from $32-36 million, with year-end cash now expected at $53-57 million.


Key Events · Earnings and Guidance · OABI

  • Q3 Revenue Doubles, Guidance Raised

    Q3 2026 revenue was $4.0 million versus $2.2 million a year ago; full-year 2026 revenue guidance rose to $35-39 million from $32-36 million.

  • Cash Outlook Lifted to $53-57M

    OmniAb held $64.2 million in cash, cash equivalents and short-term investments at September 30, 2026, and now expects to end the year with $53-57 million versus $49-53 million previously.

  • Cost Guidance Trimmed

    Costs and operating expenses guidance was lowered to $83-87 million from $84-88 million, and cash costs and operating expenses to $50-54 million from $51-55 million.

  • Lilly Ion Channel Deal Up to $370M

    A new global collaboration and license agreement with Eli Lilly for an ion channel program carries an up-front payment plus up to $370 million in research, development and commercial milestones and tiered royalties.


Analysis · OABI · Industrial Applications And Services

OmniAb's Q3 revenue of $4.0 million was up from $2.2 million a year ago, and nine-month revenue of $31.8 million already dwarfs the $10.3 million booked in all of the first nine months of 2025, largely on milestone payments. Management raised full-year revenue guidance to $35-39 million from $32-36 million and lifted the year-end cash outlook to $53-57 million from $49-53 million, while trimming the cost outlook. The company ended September with $64.2 million in cash and short-term investments, so the raised cash target extends runway rather than signaling a need to raise capital. The quarter also brought a new Eli Lilly ion channel collaboration worth up to $370 million in milestones, an expanded commercial launch of the xPloration platform, and the OmniTides peptide offering — all of which support the durability of the revenue base.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OABI was trading at $5.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $760.4M. The 52-week trading range was $1.30 to $5.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OABI - Latest Insights

OABI
Oct 30, 2026, 7:40 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $4.80 info
Change: -$0.3963 (-8%) info
Market Cap: $716.174M info
OABI
Aug 17, 2026, 6:01 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $4.80 info
Change: +$1.47 (+44%) info
Market Cap: $716.174M info
OABI
Aug 06, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $4.80 info
Change: +$2.40 (+100%) info
Market Cap: $716.174M info
OABI
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $4.80 info
Change: +$2.50 (+109%) info
Market Cap: $716.174M info
OABI
May 07, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $4.80 info
Change: +$3.33 (+227%) info
Market Cap: $716.174M info